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In the Netherlands, 10,000 to 12,500 patients per year are
diagnosed with acute pulmonary embolism (PE) [1]. The large
majority of these patients are normotensive.
Just recently, the European Society of Cardiology
(ESC) published an update of their guideline on the
diagnosis and management of acute PE [2]. Compared
with the previous version of 2008, special emphasis was
given to risk stratification in normotensive acute PE.
The algorithm was largely based on the recent PEITHO
trial [3]. In summary, the following prognostic assess-
ment has been proposed (Fig. 1).
After establishment of the diagnosis of pulmonary
embolism by CT angiography, a clinical assessment is
performed by the simplified pulmonary embolism sever-
ity index (sPESI) [4]. To calculate sPESI, one point is
scored for each of the following items: age>80 years;
history of cancer; history of heart failure and/or chronic
lung disease; heart rate ≥110 bpm; systolic blood pres-
sure<100 mmHg; arterial oxyhaemoglobin saturation
<90 %. If sPESI is 0, the patient is considered at low
risk (30-day mortality risk: 1.1 %), and is probably
eligible for home treatment with either a vitamin K
antagonist (plus low-molecular-weight heparin) or a
new oral anticoagulant. If sPESI is 1 or higher, the
patient is considered at intermediate risk (30-day mor-
tality risk: 8.9 %) and additional testing is recommend-
ed, which includes an imaging test to evaluate signs of
right ventricular (RV) dysfunction (either echocardiogra-
phy or CT) and cardiac laboratory biomarkers (prefera-
bly troponin). When both tests return positive, the pa-
tient is classified as intermediate-high risk; if only one
or neither test is positive, the patient is classified as
intermediate-low risk. The guideline recommends initia-
tion of anticoagulation and hospitalisation, and for
intermediate-high risk patients even ‘close monitoring’
is advised. At the first sign of haemodynamic decom-
pensation, rescue thrombolytic therapy is indicated.
RV failure due to pressure overload is considered the
primary cause of death in severe PE. Therefore, it is
very logical that the ESC guideline has incorporated
imaging techniques that directly evaluate RV dysfunc-
tion. However, in practice this approach could be trou-
blesome. First of all, even in the Netherlands, echocar-
diography and (to a lesser extent) CT angiography are
not always available, especially during non-office hours.
Secondly, the definition of RV dysfunction is poorly
defined: given the peculiar geometry of the right ven-
tricle, there is no individual (echocardiographic) param-
eter that provides fast and reliable information on RV
size or function.
An alternative -and potentially more practical- ap-
proach could be the sole reliance on biomarkers of RV
dysfunction. Increase of RV wall stress results in release
of troponin and (NT-pro)BNP, and therefore increased
plasma levels are found in intermediate to high risk
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patients. In this issue, Keller and coworkers provide us
some insights into the relationship between cardiac tro-
ponin I and RV dysfunction [5]. Based on their retro-
spective analysis, they found a strong association be-
tween the two, consistent with what has been reported
by others [6]. However, the positive and especially the
negative predictive value of troponin I should be con-
sidered too low to solely guide clinical management (84
and 73 %, respectively). Meta-analysis by Becattini
et al. showed that the prognostic performance of tropo-
nin T is similar to troponin I,[7] so no significant
improvement can be expected from troponin T either.
So, what about (NT-pro)BNP? Recently Jiménez
et al. prospectively evaluated the prognostic perfor-
mance of BNP, along with sPESI, RV dysfunction de-
tected by CT angiography or echocardiography, troponin
I, and lower limb ultrasound testing (PROTECT study)
[8]. They found that the combination of sPESI (of 0)
and BNP (<100 pg/mL) gives a nearly perfect negative
predictive value of 99 % (95 % confidence interval: 96–
100 %) for a 30-day complicated course (death from
any cause, haemodynamic collapse or recurrent PE).
The positive predictive value was relatively low
(26 %, 95 % confidence interval: 10–41 %). They
concluded that this combination seems an excellent
screening tool to identify low-risk PE patients from
patients with intermediate risk. Interestingly, they did
not find any support for the evaluation of RV dysfunc-
tion by either CT angiography or echocardiography as a
prognosticator in normotensive PE, which was explained
by the lack of a clear definition of RV dysfunction. The
latter would imply that current ESC risk stratification
strategy can be simplified even further.
In conclusion, the updated ESC guideline provides
clear recommendations on risk stratification in PE.
However, risk stratification in patients with normoten-
sive PE remains suboptimal. Especially the subdivision
of intermediate-low vs. intermediate-high PE patients
might be unnecessarily complicated. Future studies that
address this problem are needed.
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